Prioritizing Therapeutics for Lung Cancer: An Integrative Meta-analysis of Cancer Gene Signatures and Chemogenomic Data

PLoS Computational Biology

Volumn 11, Issue 3, 2015, Pages

  Fortney, Kristen ^a   Griesman, Joshua ^b   Kotlyar, Max ^b   Pastrello, Chiara ^b   Angeli, Marc ^b   Sound Tsao, Ming ^b   Jurisica, Igor ^a,b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; CELL CULTURE; DRUG THERAPY; FORECASTING; GENES; PIPELINES;

ANALYSIS FRAMEWORKS; CANCER GENES; CHEMOGENOMICS; GENE SIGNATURES; LUNG CANCER; META-ANALYSIS; PUBLIC DOMAINS; REPRODUCIBILITIES; REPURPOSING; TRANSCRIPTOMES;

DISEASES;

2 MORPHOLINO 8 PHENYLCHROMONE; 8 AZAGUANINE; CAMPTOTHECIN; CANTHARIDIN; CHLORPROMAZINE; CLIOQUINOL; COLCHICINE; DAUNORUBICIN; DEQUALINIUM; DOXORUBICIN; ELLIPTICINE; ENTINOSTAT; FLUSPIRILENE; MEBENDAZOLE; MENADIONE; MICONAZOLE; PHENINDIONE; PIMOZIDE; PROCHLORPERAZINE; PUROMYCIN; RAPAMYCIN; SPIPERONE; TANESPIMYCIN; THIOGUANOSINE; THIORIDAZINE; TRANSCRIPTOME; TRIFLUOPERAZINE; UNINDEXED DRUG; VIDARABINE; VORINOSTAT; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CALM1 GENE; CANCER INHIBITION; COMPUTER MODEL; DRUG IDENTIFICATION; DRUG REPOSITIONING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IN VITRO STUDY; LUNG CANCER; LUNG CANCER CELL LINE; META ANALYSIS; PLA2G4A GENE; PROTEIN TARGETING; TUMOR GENE; BIOLOGY; COMPUTER SIMULATION; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; PHARMACOGENETICS; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; PHARMACOGENETICS; PIMOZIDE;

EID: 84926385334     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004068     Document Type: Article

References (38)

1. Hayat MJ, Howlader N, Reichman ME, Edwards BK, (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. The oncologist 12: 20–37. 17227898
2. Fortney K, Jurisica I, (2011) Integrative computational biology for cancer research. Hum Genet 130: 465–481. doi: 10.1007/s00439-011-0983-z 21691773
3. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929–1935. 17008526
4. De Preter K, De Brouwer S, Van Maerken T, Pattyn F, Schramm A, et al. (2009) Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds. Clin Cancer Res Off J Am Assoc Cancer Res 15: 3690–3696.
5. Vilar E, Mukherjee B, Kuick R, Raskin L, Misek DE, et al. (2009) Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res Off J Am Assoc Cancer Res 15: 2829–2839.
6. Chang M, Smith S, Thorpe A, Barratt MJ, Karim F, (2010) Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping. Mol Pain 6: 56. doi: 10.1186/1744-8069-6-56 20846436
7. Kunkel SD, Suneja M, Ebert SM, Bongers KS, Fox DK, et al. (2011) mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab 13: 627–638. doi: 10.1016/j.cmet.2011.03.020 21641545
8. Wang G, Ye Y, Yang X, Liao H, Zhao C, et al. (2011) Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma. PloS One 6: e14573. doi: 10.1371/journal.pone.0014573 21283735
9. Ebi H, Tomida S, Takeuchi T, Arima C, Sato T, et al. (2009) Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. Cancer Res 69: 4027–4035. doi: 10.1158/0008-5472.CAN-08-3403 19383916
10. Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, et al. (2013) A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 3: 1364–1377. doi: 10.1158/2159-8290.CD-13-0183 24078773
11. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, et al. (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia N Y N 9: 166–180. 17356713
12. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, et al. (2011) Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 3: 96ra77. doi: 10.1126/scitranslmed.3001318 21849665
13. Zhang S-D, Gant TW, (2009) sscMap: an extensible Java application for connecting small-molecule drugs using gene-expression signatures. BMC Bioinformatics 10: 236. doi: 10.1186/1471-2105-10-236 19646231
14. McArt DG, Zhang S-D, (2011) Identification of candidate small-molecule therapeutics to cancer by gene-signature perturbation in connectivity mapping. PloS One 6: e16382. doi: 10.1371/journal.pone.0016382 21305029
15. Breitling R, Armengaud P, Amtmann A, Herzyk P, (2004) Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 573: 83–92. 15327980
16. Rohrbeck A, Neukirchen J, Rosskopf M, Pardillos GG, Geddert H, et al. (2008) Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers. J Transl Med 6: 69. doi: 10.1186/1479-5876-6-69 18992152
17. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, et al. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci 98: 13790–13795. 11707567
18. DTP: Developmental Therapeutics Program NCI/NIH (2012). Available: http://dtp.nci.nih.gov/.
19. Gorzalczany Y, Gilad Y, Amihai D, Hammel I, Sagi-Eisenberg R, et al. (2011) Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer. Cancer Lett 310: 207–215. doi: 10.1016/j.canlet.2011.07.002 21807458
20. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, et al. (2010) Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 28: 56–62.
21. Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, et al. (2011) Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 6: 1152–1161.
22. Wiklund ED, Catts VS, Catts SV, Ng TF, Whitaker NJ, et al. (2010) Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target. Int J Cancer J Int Cancer 126: 28–40.
23. Willett P, (2011) Similarity searching using 2D structural fingerprints. Methods Mol Biol Clifton NJ 672: 133–158. doi: 10.1007/978-1-60761-839-3_5 20838967
24. Knox C, Law V, Jewison T, Liu P, Ly S, et al. (2011) DrugBank 3.0: a comprehensive resource for “omics” research on drugs. Nucleic Acids Res 39: D1035–D1041. doi: 10.1093/nar/gkq1126 21059682
25. Seiler KP, George GA, Happ MP, Bodycombe NE, Carrinski HA, et al. (2008) ChemBank: a small-molecule screening and cheminformatics resource database. Nucleic Acids Res 36: D351–D359. 17947324
26. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, et al. (2010) Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 107: 14621–14626. doi: 10.1073/pnas.1000138107 20679242
27. Mine N, Yamamoto S, Saito N, Yamazaki S, Suda C, et al. (2011) CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin. Mol Cancer Ther 10: 1929–1938. doi: 10.1158/1535-7163.MCT-10-1139 21831962
28. Meyer AM, Dwyer-Nield LD, Hurteau GJ, Keith RL, O’Leary E, et al. (2004) Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis 25: 1517–1524. 15033900
29. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. (2004) Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 101: 9309–9314. 15184677
30. A to Z List of Cancer Drugs (n.d.). Natl Cancer Inst. Available: http://www.cancer.gov/cancertopics/druginfo/alphalist. Accessed 7 August 2014.
31. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603–607. doi: 10.1038/nature11003 22460905
32. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55. 6382953
33. Chou T-C, (2010) Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Res 70: 440–446. doi: 10.1158/0008-5472.CAN-09-1947 20068163
34. Brown KR, Otasek D, Ali M, McGuffin MJ, Xie W, et al. (2009) NAViGaTOR: Network Analysis, Visualization and Graphing Toronto. Bioinforma Oxf Engl 25: 3327–3329.
35. The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC (n.d.).
36. Bolton EE, Wang Y, Thiessen PA, Bryant SH, Ralph A, Wheeler Spellmeyer David C., (2008) Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities. In: Annual Reports in Computational Chemistry. Elsevier, Vol. Volume 4. pp. 217–241. Available: http://www.sciencedirect.com/science/article/pii/S1574140008000121. Accessed 3 February 2014.
37. Kotlyar M, Fortney K, Jurisica I, (2012) Network-based characterization of drug-regulated genes, drug targets, and toxicity. Methods San Diego Calif 57: 499–507. doi: 10.1016/j.ymeth.2012.06.003 22749929
38. Cancer Cell Culture—Methods and Protocols (2011). 2nd ed. Available: http://www.springer.com/biomed/cancer/book/978-1-61779-079-9. Accessed 3 February 2014.